In Phase I clinical trial, Avacta’s AVA6000 is being assessed to treat soft tissue sarcoma. Credit: Nephron / commons.wikimedia.org.

Avacta Group has opened the first two clinical investigator sites in the US for the Phase I clinical trial of AVA6000.

Under the US investigational new drug (IND) application, the company opened Fred Hutch Cancer Center in Seattle and Memorial Sloan Kettering Cancer Center (MSK) in New York for enrolment of participants in the trial.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The latest move marks a significant milestone in the company’s plan to expand clinical trials of its pre|CISION drug candidate, AVA6000.

The Phase I clinical trial is said to be the first-in-human trial of AVA6000 to treat soft tissue sarcoma.

Avacta stated that a Phase Ia dose escalation trial is now being conducted in the UK.

It recently started dosing participants in the fifth cohort at 250mg/m2, after AVA6000’s favourable safety profile is generated in the trial conducted to date.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Currently, enrolment of patients with soft tissue sarcoma commenced in the Phase I clinical trial in the US.

Initially, these US trial sites will provide participants for the dose escalation phase of the trial.

In the trial, participants will receive the same doses at each trial stage as in the UK.

Avacta Therapeutics chief development officer Neil Bell said: “This timely opening of these two key US sites, under the expert direction of Dr Tap and Professor Cranmer, is a major milestone in Avacta’s entry strategy into the US with our promising AVA6000 pre|CISION lead programme.

“We share with our US colleagues a clear vision to transform treatment outcomes for patients, and we look forward to working together as we continue to build the clinical evidence base for the safety and tolerability of AVA6000, in addition to the significant tumour-targeting potential of the pre|CISION platform.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact